Pharmaceutical Japan’s largest drugmaker Takeda has announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase III clinical trial evaluating Hyqvia (immune globulin Infusion 10% (human) with recombinant human hyaluronidase) for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. 22 July 2022